Edwards Lifesciences Corporation
Financials
Valuation Metrics
Edwards Lifesciences Corporation's Market Cap is $53.69B. At end of 2025 it was $49.48B. Ranked #295 of 3,116 in US market (top 9%), #216 of 1,644 on NYSE (top 13%), #18 of 203 in Health Care Equipment & Services (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $53.69B | US#295/3,116 Sec#18/203 |
| Revenue | $6.51B | US#748/3,116 Sec#41/203 |
| Net Income | $1.00B | US#541/3,116 Sec#30/203 |
| Total Assets | $13.87B | US#804/3,116 Sec#38/203 |
| Net Assets | $10.62B | US#401/3,116 Sec#23/203 |
| Employees | 16,000 | US#641/3,116 Sec#48/203 |
| Value | ||
| P/E | 53.43x | US#1,929/3,116 Sec#100/203 |
| P/B | 5.06x | US#2,229/3,116 Sec#134/203 |
| P/S | 8.24x | US#2,615/3,116 Sec#172/203 |
| EV/EBITDA | 33.43x | US#2,258/3,116 Sec#118/203 |
| FCF Yield | 2.67% | US#1,892/3,116 Sec#108/203 |
| Profitability | ||
| ROE | 9.46% | US#1,417/3,116 Sec#69/203 |
| ROA | 7.25% | US#755/3,116 Sec#44/203 |
| Op. Margin | 28.09% | US#576/3,116 Sec#14/203 |
| Revenue Growth | 14.55% | US#923/3,116 Sec#64/203 |
| Earnings Growth | -75.75% | US#1,793/3,116 Sec#97/203 |
| Financial Health | ||
| Debt Ratio | 29.59% | US#328/3,116 Sec#33/203 |
| Total Debt | $704M | US#1,704/3,116 Sec#95/203 |
| FCF | $1.43B | US#462/3,116 Sec#30/203 |
| Cash | $2.91B | US#310/3,116 Sec#17/203 |
| Current Ratio | 4.52x | US#519/3,116 Sec#46/203 |
| Net Debt/EBITDA | -1.43x | US#237/3,116 Sec#16/203 |
| Performance | ||
| 1Y Return | 13.10% | US#1,372/3,116 Sec#107/203 |
| 1M Return | 9.51% | US#1,011/3,116 Sec#103/203 |
| From 52W High | -3.16% | US#207/3,116 Sec#27/203 |
| 1Y MDD | -13.19% | US#160/3,116 Sec#5/203 |
| Trading | ||
| Volume | 10,709,499 shares | US#520/3,116 Sec#26/203 |
| Trading Value | $989M | US#323/3,116 Sec#26/203 |
| Per Share | ||
| EPS | $1.75 | US#1,418/3,116 Sec#73/203 |
| BPS | $18.44 | US#1,315/3,116 Sec#74/203 |
Company Info
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.